期刊文献+

探讨药物GLP机构致癌试验中啮齿类动物的临床检查

Explore GLP Institutions Cancer Trials Rodents in Clinical Examination
下载PDF
导出
摘要 致癌性试验主要用于评价新药潜在的致癌性风险,是药物GLP机构安全性评价的重要内容之一。致癌试验的实验周期较长,动物的临床检查是整个试验的一项重要内容,临床检查结果为动物人道终点、临床病理学检测、组织病理学检查提供直接参考依据,本文总结并归纳了2年来大鼠背景数据的临床检查经验,探讨在致癌试验中的应用,以便于为检验人员提供更加全面的动物信息。 The carcinogenic test is mainly used to evaluate the potential carcinogenic risk, and it is one of the important contents of the safety evaluation of the drug GLP mechanism. The cycle of carcinogenicity test is very long, and the animal clinical examination involved is an important part of the whole test, and the clinical examination result provide a direct reference for animal humane endpoint, clinical pathology examination, histopathological examination. Thus, we summarized two years of the experience about the rat background data, and explored the application in cancer experiment, so that the experimentalists can get a more comprehensive animal information.
作者 李春令 刘增祥 刘金鑫 孙昌华 LI Chunling;LIU Zengxiang;LIU Jinxin;SUN Changhua(Shandong Quality Inspection Center For Medical Devices,Jinan 250101 ,China;Shandong Institute for Food and Drug Control,Jinan 250101 ,China)
出处 《实验动物科学》 2019年第3期74-76,共3页 Laboratory Animal Science
关键词 GLP 致癌试验 临床检查 GLP carcinogenicity test clinical examination
  • 相关文献

参考文献5

二级参考文献34

  • 1周喆,袁素波,廖明阳.塞替派诱发人支气管上皮恶性转化成瘤细胞的生物学特性[J].中国药理学与毒理学杂志,2005,19(2):133-136. 被引量:2
  • 2张雨梅,孙侠,殷俊,潘金春.已烯雌酚致新生鼠肺肿瘤模型的建立[J].癌变.畸变.突变,2006,18(6):462-464. 被引量:2
  • 3国家食品药品监督管理局.药品注册管理办法[EB/OL].[2007-07-10].http://www.sda.gov.cn/WS01/CL0053/24529.html.
  • 4ICH. S1A : Guideline on the need for carcinogenicity study of phar- maceuticals[ EB/OL]. ( 1995 - 11 - 29 ). http ://www. ich. org.
  • 5国家食品药品监督管理局.药物致癌试验的技术指导原则[EB/OL].(2010-04-01).http://www.sfda.gov.cn.
  • 6ICH. S6 (R1) :Addendum to ICH S6 :Preclinical safety evaluation of biotechnology-derived pharmaceuticals [ EB/OL ]. (2009 - 10 - 29). http://www, ich. rog.
  • 7FDA. Guidance for industry and review staff: recommended approaches to integration of genetic toxicology study results [ EB/OL]. ( 2006 - 01 - 03 ). http ://www. fda. gov.
  • 8COHEN SM, STORER RD, CRISWELL KA, et al. Hemangiosarcoma in rodents: mode-of-action evaluation and human relevance [ J ]. Toxicol Sci, 2009,111 ( 1 ) :4 - 18.
  • 9HOLSAPPLE MP, PITOT HC, COHEN SM, et al. Mode of action in relevance of rodent liver tumors to human cancer risk[ J]. Toxicol Sci, 2006,89(1) :51 -56.
  • 10Cohen SM,Robinson D,MacDonald J.Alternative models for carcinogenicity testing[J].Toxicol Sci,2001,64(1):14-19.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部